Ileal transposition helps to regulate plasma hepatokine levels in obese Zucker (Crl:ZUC(ORL)-Leprfa) rats

Stygar, Dominika; Sawczyn, Tomasz; Dulska, Agnieszka; Chełmecka, Elżbieta; Mielańczyk, Łukasz; Matysiak, Natalia; Kukla, Michał; Idzik, Maciej; Augustyniak, Jan; Gabriel, Andrzej; Karcz, Konrad; Jochem, Jerzy

doi:10.1038/s41598-021-87293-w

Cited by 2 publications

(1 citation statement)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in HFD-fed male Wistar rats, LSG can reduce weight with decreased FGF21 [153]. Consistently, one study reported that three months after ileal transposition metabolic surgery, serum FGF21 levels were lower in obese Zucker rats [154]. Moreover, in research containing 137 obese patients with insulin resistance and high baseline FGF21, FGF21 concentrations were decreased after LSGinduced weight loss.…”

Section: Relationship Between Fgf21 and Obesitymentioning

confidence: 79%

Targeting FGF21 in cardiovascular and metabolic diseases: from mechanism to medicine

Tan¹,

Tong²,

Chen³

et al. 2023

Int. J. Biol. Sci.

View full text Add to dashboard Cite

Cardiovascular and metabolic disease (CVMD) is becoming increasingly prevalent in developed and developing countries with high morbidity and mortality. In recent years, fibroblast growth factor 21 (FGF21) has attracted intensive research interest due to its purported role as a potential biomarker and critical player in CVMDs, including atherosclerosis, coronary artery disease, myocardial infarction, hypoxia/reoxygenation injury, heart failure, type 2 diabetes, obesity, and nonalcoholic steatohepatitis. This review summarizes the recent developments in investigating the role of FGF21 in CVMDs and explores the mechanism whereby FGF21 regulates the development of CVMDs. Novel molecular targets and related pathways of FGF21 (adenosine 5'-monophosphate-activated protein kinase, silent information regulator 1, autophagy-related molecules, and gut microbiota-related molecules) are highlighted in this review. Considering the poor pharmacokinetics and biophysical properties of native FGF21, the development of new generations of FGF21-based drugs has tremendous therapeutic potential. Related preclinical and clinical studies are also summarized in this review to foster clinical translation. Thus, our review provides a timely and insightful overview of the physiology, biomarker potential, molecular targets, and therapeutic potential of FGF21 in CVMDs.

show abstract

Section: Relationship Between Fgf21 and Obesitymentioning

confidence: 79%

Targeting FGF21 in cardiovascular and metabolic diseases: from mechanism to medicine

Tan¹,

Tong²,

Chen³

et al. 2023

Int. J. Biol. Sci.

View full text Add to dashboard Cite

show abstract

Retinol binding protein 4 and type 2 diabetes: from insulin resistance to pancreatic β-cell function

Fan,

2024

Endocrine

View full text Add to dashboard Cite

Background and aim Retinol binding protein 4 (RBP4) is an adipokine that has been explored as a key biomarker of type 2 diabetes mellitus (T2DM) in recent years. Researchers have conducted a series of experiments to understand the interplay between RBP4 and T2DM, including its role in insulin resistance and pancreatic β-cell function. The results of these studies indicate that RBP4 has a significant influence on T2DM and is considered a potential biomarker of T2DM. However, there have also been some controversies about the relationship between RBP4 levels and T2DM. In this review, we update and summarize recent studies focused on the relationship between RBP4 and T2DM and its role in insulin resistance and pancreatic β-cell function to clarify the existing controversy and provide evidence for future studies. We also assessed the potential therapeutic applications of RBP4 in treating T2DM. Methods A narrative review. Results Overall, there were significant associations between RBP4 levels, insulin resistance, pancreatic β-cell function, and T2DM. Conclusions More mechanistic studies are needed to determine the role of RBP4 in the onset of T2DM, especially in terms of pancreatic β-cell function. In addition, further studies are required to evaluate the effects of drug intervention, lifestyle intervention, and bariatric surgery on RBP4 levels to control T2DM and the role of reducing RBP4 levels in improving insulin sensitivity and pancreatic β-cell function.

show abstract

Ileal transposition helps to regulate plasma hepatokine levels in obese Zucker (Crl:ZUC(ORL)-Leprfa) rats

Cited by 2 publications

References 59 publications

Targeting FGF21 in cardiovascular and metabolic diseases: from mechanism to medicine

Targeting FGF21 in cardiovascular and metabolic diseases: from mechanism to medicine

Retinol binding protein 4 and type 2 diabetes: from insulin resistance to pancreatic β-cell function

Contact Info

Product

Resources

About